Amicus Therapeutics, Inc.
FOLD
Helyezés a részvények között
#3707
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Részvényárfolyam
$14.49
Utolsó szinkronizálás: 2026-04-27
Piaci kapitalizáció
$4.55B
Változás (1 nap)
0.00%
Változás (1 év)
71.68%
Ország
US
Kereskedés Amicus Therapeutics, Inc. (FOLD)
Kategória
Healthcare
Amicus Therapeutics, Inc. (FOLD) P/S aránya
P/S arány ekkor: October 2026 TTM: 8.94
Amicus Therapeutics, Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi árbevétel aránya (P/S, TTM) 8.94. 2023 végén ez az arány 10.49 volt.
P/S arány története a(z) Amicus Therapeutics, Inc. esetén 2003 és 2026 között
P/S arány az év végén
| Év | P/S arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 8.94 | 64.63% |
| 2024 | 5.43 | -48.25% |
| 2023 | 10.49 | -2.17% |
| 2022 | 10.72 | 4.47% |
| 2021 | 10.26 | -55.21% |
| 2020 | 22.91 | 78.30% |
| 2019 | 12.85 | -34.13% |
| 2018 | 19.51 | -67.36% |
| 2017 | 59.76 | -55.65% |
| 2016 | 134.73 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | 506.03 | 52.41% |
| 2013 | 332.02 | 4,905.76% |
| 2012 | 6.63 | 19.55% |
| 2011 | 5.55 | -96.08% |
| 2010 | 141.38 | 10,030.50% |
| 2009 | 1.40 | -88.36% |
| 2008 | 11.99 | -84.96% |
| 2007 | 79.76 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
P/S arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/S arány | P/S arány különbség | Ország |
|---|---|---|---|
| 10.02 | 12.11% |
US
|
|
| 40.55 | 353.61% |
US
|
|
| 3.96 | -55.69% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 13.50% |
NL
|
